A Phase 3 interventional study of Alogliptin and Alogliptin placebo in Type 2 Diabetes Mellitus, sponsored by Takeda. Completed at 90 sites in 19 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-04-04.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 23 · Phase 4 9
First in 2005; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,554 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 39 interventional studies. Of the 35 that completed or were terminated, 30 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 8th largest by enrollment of the 85 interventional ones that give a count, is one of 13 that started in 2006, is one of 45 in phase 3, and was the 11th registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
Over the past 30 years, the prevalence of diabetes has increased dramatically throughout the world due to population growth, aging, urbanization, increasing obesity, and physical inactivity. The total number of people with type 2 diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. The incidence of type 2 diabetes mellitus in the United States alone is expected to increase from approximately 17 to 30.3 million by the year 2030. Type 2 diabetes mellitus is associated with a number of long-term microvascular and macrovascular complications associated with a reduced quality of life and increased morbidity and mortality. It is anticipated that the increasing incidence of type 2 diabetes mellitus will place an ever-increasing burden on families, increase national expenditures for health care services, and decrease worker productivity.
Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of antidiabetic medications with different mechanisms of action including insulin and insulin analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha-glucosidase, analogs of glucagon-like peptide-1 and synthetic analogues of human amylin. Despite the variety of medications, many have clinically important or potentially life-threatening side effects, restricted use in many subpopulations, concerns with long-term tolerability, and challenges related to compliance due to side effects and route of administration. All of these reasons contribute to the difficulties patients have achieving the target glycosylated hemoglobin level less than 7%.
SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4 enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus.
Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output.
Given the complementary mechanisms of action of alogliptin (stimulation of insulin secretion) and pioglitazone (enhancement of insulin sensitivity), the goal of this study is to evaluate the efficacy of the combination of alogliptin with pioglitazone in patients who are inadequately controlled on metformin. Study participation is anticipated to be approximately 7 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin placebo · Drug: Pioglitazone placebo
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone placebo
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone placebo
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Pioglitazone
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin placebo · Drug: Pioglitazone
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin placebo · Drug: Pioglitazone
Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
Drug: Alogliptin · Drug: Pioglitazone
Alogliptin tablets.
Also known as: SYR-322
Alogliptin placebo-matching tablets.
Pioglitazone tablets.
Also known as: ACTOS®
Pioglitazone placebo-matching tablets.
Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The primary analysis compared the groupings (combinations of individual treatment groups) of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone (Pioglitazone Alone).
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in HbA1c
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Time frame: Baseline and Week 26
Change From Baseline in HbA1c Over Time (Grouped Analysis)
The change from Baseline to Weeks 4, 8, 12, 16 and 20 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as class variables, and baseline metformin dose and HbA1c as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16 and 20.
Change From Baseline to Week 4 in HbA1c
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 4. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in HbA1c
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 8. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in HbA1c
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in HbA1c
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 16. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in HbA1c
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 20. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline in Fasting Plasma Glucose Over Time (Grouped Analysis)
The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 1 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 1
Change From Baseline to Week 2 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 2
Change From Baseline to Week 4 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Fasting Plasma Glucose
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
Time frame: Baseline and Week 26
Percentage of Participants With Marked Hyperglycemia (Grouped Analysis)
Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: From Week 1 to Week 26
Percentage of Participants With Marked Hyperglycemia
Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L).
Time frame: From Week 1 to Week 26
Percentage of Participants Meeting Rescue Criteria (Grouped Analysis)
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.
Time frame: From Week 1 to Week 26.
Percentage of Participants Meeting Rescue Criteria
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.
Time frame: From Week 1 to Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 7%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Week 26
Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%.
Time frame: Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%.
Time frame: Baseline and Week 26
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis)
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
Time frame: Baseline and Week 26.
Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2%
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2%.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Proinsulin Over Time (Grouped Analysis)
Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and proinsulin as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Fasting Proinsulin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Insulin Over Time (Grouped Analysis)
The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Insulin Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Proinsulin/Insulin Ratio Over Time (Grouped Analysis)
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Proinsulin/Insulin Ratio
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in C-peptide Over Time (Grouped Analysis)
C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in C-peptide Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Total Cholesterol Over Time (Grouped Analysis)
Change from Baseline in total cholesterol was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Total Cholesterol Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Low-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)
Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in High-Density Lipoprotein Cholesterol Over Time (Grouped Analysis)
Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in High-Density Lipoprotein Cholesterol
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Triglycerides Over Time (Grouped Analysis)
Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20 and 26.
Change From Baseline to Week 4 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 4
Change From Baseline to Week 8 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 16 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 16
Change From Baseline to Week 20 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Triglyceride Levels
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Free Fatty Acids Over Time (Grouped Analysis)
Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in Free Fatty Acids
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Free Fatty Acids
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Plasminogen Activator Inhibitor-1 Over Time (Grouped Analysis)
Change from Baseline in plasminogen activator inhibitor-1 (PAI-1) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in Plasminogen Activator Inhibitor-1
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Plasminogen Activator Inhibitor-1
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in High-sensitivity C-Reactive Protein Over Time (Grouped Analysis)
Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in High-sensitivity C-Reactive Protein
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in High-sensitivity C-Reactive Protein
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Adiponectin Over Time (Grouped Analysis)
Change from Baseline in adiponectin was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in Adiponectin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Adiponectin
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight Over Time (Grouped Analysis)
Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
Time frame: Baseline and Weeks 8, 12, 20 and 26.
Change From Baseline to Week 8 in Body Weight
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
Time frame: Baseline and Week 8
Change From Baseline to Week 12 in Body Weight
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 20 in Body Weight
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
Time frame: Baseline and Week 20
Change From Baseline to Week 26 in Body Weight
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) (Grouped Analysis)
HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in Calculated HOMA Insulin Resistance
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Calculated HOMA Insulin Resistance
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Homeostatic Model Assessment Beta Cell Function (Grouped Analysis)
The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Calculated HOMA Beta-cell Function
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Calculated HOMA Beta-cell Function
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Apolipoprotein A1 Over Time (Grouped Analysis)
Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in Apolipoprotein A1
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Apolipoprotein A1
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Apolipoprotein A2 Over Time (Grouped Analysis)
Change from Baseline in Apolipoprotein A2 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Apolipoprotein A2
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Apolipoprotein A2
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Apolipoprotein B Over Time (Grouped Analysis)
Change from Baseline in Apolipoprotein B was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Apolipoprotein B
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Apolipoprotein B
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Apolipoprotein C-III Over Time (Grouped Analysis)
Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Apolipoprotein C-III
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Apolipoprotein C-III
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides Over Time (Grouped Analysis)
Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides
NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides
NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles Over Time (Grouped Analysis)
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in VLDL / Chylomicron Particles
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in VLDL / Chylomicron Particles
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in VLDL / Chylomicron Triglycerides Over Time (Grouped Analysis)
The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in VLDL / Chylomicron Triglycerides
The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in VLDL / Chylomicron Triglycerides
The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in VLDL Particles Over Time (Grouped Analysis)
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in VLDL Particles
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in VLDL Particles
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates
Time frame: Baseline and Week 26
Change From Baseline in Mean VLDL Particle Size Over Time (Grouped Analysis)
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Mean VLDL Particle Size
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Mean VLDL Particle Size
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles Over Time (Grouped Analysis)
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in IDL Particles
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in IDL Particles
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Low Density Lipoprotein (LDL) Particles Over Time (Grouped Analysis)
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in LDL Particles
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in LDL Particles
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Mean LDL Particle Size Over Time (Grouped Analysis)
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Mean LDL Particle Size
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Mean LDL Particle Size
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in High Density Lipoprotein (HDL) Particles Over Time (Grouped Analysis)
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
Time frame: Baseline and Weeks 12 and 26.
Change From Baseline to Week 12 in HDL Particles
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in HDL Particles
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
Time frame: Baseline and Week 26
Change From Baseline in Mean HDL Particle Size Over Time (Grouped Analysis)
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
Time frame: Baseline and Weeks 12 and 26
Change From Baseline to Week 12 in Mean HDL Particle Size
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
Time frame: Baseline and Week 12
Change From Baseline to Week 26 in Mean HDL Particle Size
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
Time frame: Baseline and Week 26
Participants took part in the study at 327 investigative sites in 20 countries from 31 May 2006 to 17 March 2008.
| Milestone | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 129 | 128 | 129 | 130 | 130 | 130 | 129 | 130 | 130 | 129 | 130 | 130 |
| Safety set | 129 | 128 | 129 | 129 | 130 | 130 | 129 | 130 | 130 | 129 | 130 | 130 |
| Completed | 70 | 97 | 101 | 93 | 115 | 110 | 94 | 116 | 113 | 97 | 112 | 114 |
| Not completed | 59 | 31 | 28 | 37 | 15 | 20 | 35 | 14 | 17 | 32 | 18 | 16 |
| Withdrew: Hyperglycemic rescue | 41 | 18 | 16 | 13 | 6 | 5 | 19 | 6 | 6 | 11 | 3 | 2 |
| Withdrew: Adverse event | 3 | 1 | 2 | 3 | 1 | 2 | 1 | 2 | 0 | 7 | 5 | 4 |
| Withdrew: Protocol violation | 2 | 2 | 2 | 8 | 5 | 5 | 6 | 2 | 1 | 4 | 6 | 2 |
| Withdrew: Lost to follow-up | 4 | 2 | 2 | 4 | 0 | 2 | 3 | 0 | 3 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 | 5 | 6 | 2 | 5 | 4 | 4 | 4 | 5 | 2 | 7 |
| Withdrew: Pregnancy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 3 | 1 | 2 | 1 | 1 | 1 | 0 | 3 | 2 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 |
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The primary analysis compared the groupings (combinations of individual treatment groups) of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone (Pioglitazone Alone).
| percentage of glycosylated hemoglobin | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis) | -0.89 ± 0.046 | -1.43 ± 0.046 | -1.42 ± 0.046 |
The change from Baseline to Weeks 4, 8, 12, 16 and 20 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as class variables, and baseline metformin dose and HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=345, 359, 346) | -0.32 ± 0.023 | -0.57 ± 0.023 | -0.61 ± 0.023 |
| Week 8 (n=376, 385, 377) | -0.61 ± 0.034 | -1.06 ± 0.033 | -1.09 ± 0.034 |
| Week 12 (n=376, 385, 377) | -0.81 ± 0.039 | -1.29 ± 0.039 | -1.38 ± 0.039 |
| Week 16 (n=376, 385, 377) | -0.92 ± 0.041 | -1.44 ± 0.041 | -1.49 ± 0.041 |
| Week 20 (n=376, 385, 377) | -0.92 ± 0.043 | -1.46 ± 0.042 | -1.51 ± 0.043 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 4. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in HbA1c | -0.22 ± 0.039 | -0.46 ± 0.040 | -0.51 ± 0.041 | -0.32 ± 0.040 | -0.53 ± 0.039 | -0.61 ± 0.040 | -0.24 ± 0.040 | -0.60 ± 0.039 | -0.60 ± 0.039 | -0.40 ± 0.040 | -0.58 ± 0.040 | -0.63 ± 0.040 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 8. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 mg + Pioglitazone 30 mg | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 mg | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in HbA1c | -0.30 ± 0.058 | -0.75 ± 0.059 | -0.80 ± 0.059 | -0.50 ± 0.058 | -1.01 ± 0.058 | -1.04 ± 0.058 | -0.57 ± 0.059 | -1.05 ± 0.058 | -1.02 ± 0.059 | -0.76 ± 0.058 | -1.11 ± 0.058 | -1.20 ± 0.058 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 mg + Pioglitazone 30 mg | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 mg | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in HbA1c | -0.28 ± 0.067 | -0.84 ± 0.069 | -0.92 ± 0.068 | -0.65 ± 0.067 | -1.24 ± 0.066 | -1.26 ± 0.067 | -0.77 ± 0.068 | -1.29 ± 0.067 | -1.33 ± 0.068 | -1.02 ± 0.067 | -1.34 ± 0.067 | -1.53 ± 0.067 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 16. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 mg + Pioglitazone 30 mg | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 mg | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in HbA1c | -0.27 ± 0.071 | -0.82 ± 0.072 | -1.03 ± 0.072 | -0.74 ± 0.071 | -1.36 ± 0.070 | -1.36 ± 0.071 | -0.91 ± 0.072 | -1.42 ± 0.071 | -1.45 ± 0.072 | -1.12 ± 0.071 | -1.53 ± 0.071 | -1.66 ± 0.071 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at week 20. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HbA1c as continuous covariates.
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 mg + Pioglitazone 30 mg | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 mg | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in HbA1c | -0.24 ± 0.074 | -0.75 ± 0.075 | -0.99 ± 0.075 | -0.75 ± 0.074 | -1.39 ± 0.073 | -1.37 ± 0.074 | -0.90 ± 0.075 | -1.43 ± 0.074 | -1.49 ± 0.075 | -1.10 ± 0.074 | -1.57 ± 0.074 | -1.66 ± 0.074 |
The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 1 (n=358, 355, 354) | -4.1 ± 1.56 | -22.6 ± 1.57 | -23.1 ± 1.57 |
| Week 2 (n=379, 383, 381) | -11.3 ± 1.62 | -30.3 ± 1.61 | -31.6 ± 1.62 |
| Week 4 (n=381, 386, 383) | -19.9 ± 1.67 | -36.8 ± 1.66 | -39.8 ± 1.67 |
| Week 8 (n=381, 386, 383) | -27.3 ± 1.77 | -42.3 ± 1.76 | -45.2 ± 1.77 |
| Week 12 (n=381, 386, 383) | -30.3 ± 1.84 | -45.0 ± 1.83 | -47.6 ± 1.83 |
| Week 16 (n=381, 386, 383) | -27.9 ± 1.86 | -43.7 ± 1.85 | -45.4 ± 1.86 |
| Week 20 (n=381, 386, 383) | -28.1 ± 2.00 | -43.6 ± 1.99 | -45.0 ± 1.99 |
| Week 26 (n=381, 386, 383) | -28.3 ± 2.03 | -45.2 ± 2.02 | -44.2 ± 2.03 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 1 in Fasting Plasma Glucose | 1.8 ± 2.67 | -14.5 ± 2.77 | -18.6 ± 2.73 | -6.1 ± 2.70 | -21.3 ± 2.69 | -20.9 ± 2.66 | 0.4 ± 2.73 | -23.2 ± 2.71 | -23.2 ± 2.72 | -6.7 ± 2.69 | -23.2 ± 2.76 | -25.0 ± 2.78 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 2 in Fasting Plasma Glucose | 4.8 ± 2.78 | -21.9 ± 2.88 | -18.9 ± 2.82 | -10.4 ± 2.80 | -30.1 ± 2.80 | -31.7 ± 2.78 | -4.3 ± 2.83 | -30.0 ± 2.79 | -31.3 ± 2.81 | -19.3 ± 2.79 | -30.8 ± 2.79 | -31.7 ± 2.81 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Fasting Plasma Glucose | 3.8 ± 2.87 | -20.4 ± 2.95 | -22.8 ± 2.92 | -20.2 ± 2.90 | -35.3 ± 2.87 | -37.3 ± 2.86 | -13.4 ± 2.92 | -37.4 ± 2.88 | -36.0 ± 2.91 | -26.1 ± 2.87 | -37.8 ± 2.89 | -46.2 ± 2.89 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Fasting Plasma Glucose | 5.7 ± 3.05 | -19.5 ± 3.14 | -19.3 ± 3.09 | -22.2 ± 3.07 | -42.3 ± 3.05 | -39.3 ± 3.04 | -24.0 ± 3.10 | -40.5 ± 3.05 | -44.1 ± 3.08 | -35.6 ± 3.05 | -44.0 ± 3.06 | -52.3 ± 3.07 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Fasting Plasma Glucose | 3.4 ± 3.16 | -19.3 ± 3.25 | -23.3 ± 3.19 | -23.0 ± 3.18 | -42.9 ± 3.16 | -42.5 ± 3.14 | -26.6 ± 3.21 | -42.8 ± 3.16 | -49.0 ± 3.19 | -41.3 ± 3.16 | -49.2 ± 3.17 | -51.4 ± 3.18 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Fasting Plasma Glucose | 1.4 ± 3.20 | -16.2 ± 3.29 | -22.6 ± 3.24 | -21.2 ± 3.22 | -41.6 ± 3.20 | -39.1 ± 3.19 | -26.3 ± 3.25 | -41.5 ± 3.20 | -43.4 ± 3.24 | -36.3 ± 3.20 | -47.9 ± 3.21 | -53.8 ± 3.22 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Fasting Plasma Glucose | 6.7 ± 3.43 | -8.7 ± 3.53 | -23.5 ± 3.48 | -22.4 ± 3.46 | -43.0 ± 3.43 | -39.3 ± 3.42 | -26.3 ± 3.49 | -41.1 ± 3.44 | -43.1 ± 3.47 | -35.7 ± 3.43 | -46.8 ± 3.45 | -52.4 ± 3.46 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline fasting plasma glucose as covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Fasting Plasma Glucose | 6.5 ± 3.50 | -13.2 ± 3.59 | -18.6 ± 3.54 | -23.6 ± 3.52 | -42.0 ± 3.50 | -38.0 ± 3.48 | -28.8 ± 3.55 | -42.2 ± 3.50 | -41.7 ± 3.54 | -32.4 ± 3.49 | -51.3 ± 3.51 | -52.7 ± 3.52 |
Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L). This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With Marked Hyperglycemia (Grouped Analysis) | 39.4 | 24.6 | 22.1 |
Marked hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L).
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Marked Hyperglycemia | 60.5 | 42.6 | 39.7 | 37.8 | 27.1 | 22.3 | 39.2 | 26.4 | 23.6 | 41.1 | 20.3 | 20.5 |
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants Meeting Rescue Criteria (Grouped Analysis) | 11.4 | 3.9 | 3.4 |
Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days of the first and analyzed by the central laboratory: 1. After the Week 1 Visit but prior to the Week 4 Visit: a single fasting plasma glucose ≥300 mg/dL; 2. From the Week 4 Visit but prior to the Week 8 Visit: a single fasting plasma glucose ≥275 mg/dL; 3. From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥250 mg/dL; 4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with Baseline HbA1c.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Meeting Rescue Criteria | 32.8 | 14.5 | 12.8 | 10.2 | 4.7 | 3.9 | 15.4 | 4.8 | 4.9 | 8.7 | 2.4 | 1.6 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% (Grouped Analysis) | 12.4 | 27.9 | 29.2 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5% | 0.8 | 8.6 | 12.4 | 6.2 | 21.5 | 24.6 | 11.6 | 30.0 | 30.0 | 19.4 | 32.3 | 33.1 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0% (Grouped Analysis) | 30.5 | 54.6 | 55.9 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 7% | 6.2 | 22.7 | 27.1 | 25.6 | 49.2 | 54.6 | 29.5 | 53.1 | 53.1 | 36.4 | 61.5 | 60.0 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% (Grouped Analysis) | 54.8 | 77.4 | 74.1 |
Clinical response at Week 26 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5% | 24.8 | 38.3 | 55.0 | 51.9 | 77.7 | 71.5 | 55.8 | 73.8 | 72.3 | 56.6 | 80.8 | 78.5 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% (Grouped Analysis) | 67.2 | 85.6 | 83.3 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5% | 31.8 | 57.8 | 66.7 | 61.2 | 86.2 | 79.2 | 68.2 | 86.9 | 83.8 | 72.1 | 83.8 | 86.9 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% (Grouped Analysis) | 45.7 | 71.8 | 69.5 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1% | 16.3 | 33.6 | 47.3 | 36.4 | 69.2 | 66.9 | 46.5 | 73.1 | 69.2 | 54.3 | 73.1 | 72.3 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% (Grouped Analysis) | 27.6 | 45.9 | 50.3 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5% | 5.4 | 15.6 | 28.7 | 21.7 | 41.5 | 46.2 | 27.1 | 45.4 | 46.2 | 34.1 | 50.8 | 58.5 |
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
| percentage of glycosylated hemoglobin | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in HbA1c | -0.13 ± 0.080 | -0.64 ± 0.081 | -0.90 ± 0.081 | -0.75 ± 0.079 | -1.34 ± 0.078 | -1.27 ± 0.079 | -0.92 ± 0.081 | -1.39 ± 0.079 | -1.39 ± 0.080 | -1.00 ± 0.080 | -1.55 ± 0.079 | -1.60 ± 0.080 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone.
| percentage of participants | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0% (Grouped Analysis) | 11.1 | 25.4 | 27.7 |
Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2%.
| percentage of participants | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2% | 1.6 | 7.8 | 11.6 | 7.0 | 23.1 | 21.5 | 9.3 | 22.3 | 26.2 | 17.1 | 30.8 | 35.4 |
Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and proinsulin as continuous covariates.
| pmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=328, 319, 327) | -6.2 ± 0.81 | -10.3 ± 0.82 | -10.1 ± 0.81 |
| Week 8 (n=357, 347, 358) | -7.2 ± 0.87 | -11.3 ± 0.88 | -11.3 ± 0.87 |
| Week 12 (n=357, 347, 358) | -8.2 ± 0.91 | -11.6 ± 0.93 | -11.6 ± 0.91 |
| Week 16 (n=358, 348, 358) | -7.2 ± 0.92 | -12.2 ± 0.94 | -11.3 ± 0.92 |
| Week 20 (n=358, 349, 359) | -6.6 ± 1.08 | -10.4 ± 1.09 | -10.7 ± 1.08 |
| Week 26 (n=358, 349, 359) | -5.3 ± 1.09 | -10.6 ± 1.11 | -9.5 ± 1.09 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Fasting Proinsulin | -0.1 ± 1.36 | -4.7 ± 1.39 | -2.3 ± 1.41 | -4.8 ± 1.42 | -9.9 ± 1.41 | -8.9 ± 1.41 | -6.7 ± 1.40 | -9.6 ± 1.43 | -9.5 ± 1.37 | -7.2 ± 1.39 | -11.3 ± 1.43 | -11.7 ± 1.44 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Fasting Proinsulin | 0.7 ± 1.48 | 0.2 ± 1.50 | -2.6 ± 1.48 | -3.8 ± 1.49 | -11.1 ± 1.50 | -10.7 ± 1.50 | -8.8 ± 1.52 | -11.8 ± 1.54 | -9.4 ± 1.50 | -9.0 ± 1.50 | -11.0 ± 1.53 | -13.8 ± 1.50 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Fasting Proinsulin | -1.0 ± 1.56 | -0.7 ± 1.57 | -2.3 ± 1.56 | -5.3 ± 1.57 | -10.1 ± 1.58 | -8.8 ± 1.58 | -11.2 ± 1.60 | -12.1 ± 1.63 | -12.7 ± 1.58 | -8.1 ± 1.58 | -12.7 ± 1.61 | -13.2 ± 1.58 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Fasting Proinsulin | -3.0 ± 1.58 | 0.0 ± 1.60 | -2.3 ± 1.58 | -3.7 ± 1.59 | -11.0 ± 1.60 | -8.4 ± 1.60 | -10.0 ± 1.62 | -12.6 ± 1.65 | -11.2 ± 1.60 | -8.0 ± 1.60 | -13.0 ± 1.63 | -14.4 ± 1.60 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Fasting Proinsulin | -0.9 ± 1.85 | 1.5 ± 1.86 | -3.0 ± 1.84 | -3.4 ± 1.86 | -11.2 ± 1.86 | -8.7 ± 1.86 | -9.3 ± 1.89 | -10.0 ± 1.92 | -10.7 ± 1.87 | -7.1 ± 1.86 | -10.2 ± 1.90 | -12.5 ± 1.87 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin as continuous covariates.
| pmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Fasting Proinsulin | 1.2 ± 1.87 | 0.7 ± 1.88 | -3.3 ± 1.86 | -3.5 ± 1.88 | -10.9 ± 1.88 | -7.2 ± 1.88 | -8.4 ± 1.91 | -8.9 ± 1.95 | -8.8 ± 1.89 | -4.1 ± 1.89 | -12.1 ± 1.93 | -12.6 ± 1.89 |
The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=325, 318, 326) | -2.29 ± 0.440 | -2.11 ± 0.445 | -2.19 ± 0.440 |
| Week 8 (n=355, 346, 356) | -2.35 ± 0.535 | -2.44 ± 0.542 | -2.36 ± 0.534 |
| Week 12 (n=355, 347, 356) | -2.62 ± 0.498 | -1.73 ± 0.503 | -2.62 ± 0.497 |
| Week 16 (n=356, 348, 356) | -2.19 ± 0.488 | -2.60 ± 0.494 | -2.48 ± 0.488 |
| Week 20 (n=356, 349, 357) | -2.35 ± 0.511 | -1.91 ± 0.516 | -2.06 ± 0.510 |
| Week 26 (n=356, 349, 357) | -1.74 ± 1.212 | -2.05 ± 1.225 | -1.66 ± 1.210 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Insulin Levels | 1.06 ± 0.737 | -0.33 ± 0.756 | 2.31 ± 0.771 | -1.68 ± 0.767 | -3.03 ± 0.760 | -1.86 ± 0.763 | -2.43 ± 0.760 | -1.45 ± 0.779 | -2.05 ± 0.743 | -2.76 ± 0.760 | -1.85 ± 0.774 | -2.65 ± 0.778 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Insulin Levels | -0.46 ± 0.912 | 1.80 ± 0.923 | 1.69 ± 0.909 | -1.47 ± 0.916 | -2.21 ± 0.923 | -2.78 ± 0.923 | -2.74 ± 0.935 | -3.15 ± 0.953 | -1.20 ± 0.927 | -2.83 ± 0.927 | -1.96 ± 0.939 | -3.09 ± 0.924 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Insulin Levels | 0.06 ± 0.849 | 1.79 ± 0.859 | 1.93 ± 0.846 | -1.29 ± 0.852 | -1.47 ± 0.859 | -2.01 ± 0.859 | -3.61 ± 0.870 | -1.36 ± 0.882 | -2.83 ± 0.863 | -2.95 ± 0.863 | -2.35 ± 0.874 | -3.01 ± 0.859 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Insulin Levels | 0.34 ± 0.833 | 1.22 ± 0.843 | 1.83 ± 0.830 | -0.63 ± 0.836 | -2.28 ± 0.840 | -1.11 ± 0.843 | -3.46 ± 0.851 | -2.50 ± 0.866 | -2.82 ± 0.847 | -2.48 ± 0.847 | -3.00 ± 0.858 | -3.52 ± 0.844 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Insulin Levels | 0.18 ± 0.873 | 2.03 ± 0.883 | 0.76 ± 0.869 | -0.66 ± 0.876 | -2.35 ± 0.876 | -0.90 ± 0.880 | -3.29 ± 0.891 | -2.20 ± 0.907 | -2.29 ± 0.887 | -3.12 ± 0.887 | -1.16 ± 0.899 | -3.01 ± 0.884 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline insulin as continuous covariates.
| µIU/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Insulin Levels | 6.78 ± 2.071 | 1.33 ± 2.096 | 1.43 ± 2.063 | -0.78 ± 2.078 | -3.05 ± 2.078 | -0.76 ± 2.087 | -2.56 ± 2.114 | -0.76 ± 2.152 | -1.42 ± 2.105 | -1.88 ± 2.105 | -2.33 ± 2.132 | -2.79 ± 2.096 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=325, 315, 326) | -0.021 ± 0.0088 | -0.078 ± 0.0089 | -0.057 ± 0.0088 |
| Week 8 (n=355, 344, 356) | -0.019 ± 0.0084 | -0.079 ± 0.0086 | -0.081 ± 0.0084 |
| Week 12 (n=355, 345, 356) | -0.042 ± 0.0083 | -0.086 ± 0.0084 | -0.082 ± 0.0083 |
| Week 16 (n=356, 346, 356) | -0.033 ± 0.0077 | -0.091 ± 0.0078 | -0.077 ± 0.0077 |
| Week 20 (n=356, 347, 357) | -0.034 ± 0.0076 | -0.088 ± 0.0077 | -0.078 ± 0.0076 |
| Week 26 (n=356, 347, 357) | -0.027 ± 0.0088 | -0.087 ± 0.0090 | -0.076 ± 0.0088 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Proinsulin/Insulin Ratio | -0.015 ± 0.0147 | -0.039 ± 0.0151 | -0.058 ± 0.0154 | -0.029 ± 0.0153 | -0.054 ± 0.0153 | -0.054 ± 0.0153 | -0.023 ± 0.0152 | -0.068 ± 0.0157 | -0.045 ± 0.0149 | -0.009 ± 0.0152 | -0.111 ± 0.0155 | -0.072 ± 0.0156 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Proinsulin/Insulin Ratio | 0.005 ± 0.0144 | -0.025 ± 0.0146 | -0.045 ± 0.0143 | -0.007 ± 0.0144 | -0.086 ± 0.0146 | -0.077 ± 0.0146 | -0.036 ± 0.0148 | -0.054 ± 0.0152 | -0.072 ± 0.0146 | -0.013 ± 0.0146 | -0.098 ± 0.0148 | -0.093 ± 0.0146 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Proinsulin/Insulin Ratio | -0.006 ± 0.0142 | -0.024 ± 0.0144 | -0.041 ± 0.0141 | -0.041 ± 0.0142 | -0.073 ± 0.0144 | -0.056 ± 0.0144 | -0.063 ± 0.0146 | -0.072 ± 0.0149 | -0.088 ± 0.0144 | -0.021 ± 0.0144 | -0.112 ± 0.0146 | -0.101 ± 0.0144 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Proinsulin/Insulin Ratio | -0.026 ± 0.0132 | -0.036 ± 0.0133 | -0.046 ± 0.0131 | -0.035 ± 0.0132 | -0.078 ± 0.0133 | -0.066 ± 0.0134 | -0.035 ± 0.0135 | -0.094 ± 0.0138 | -0.061 ± 0.0134 | -0.030 ± 0.0134 | -0.102 ± 0.0136 | -0.104 ± 0.0133 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Proinsulin/Insulin Ratio | -0.007 ± 0.0131 | -0.014 ± 0.0132 | -0.046 ± 0.0130 | -0.039 ± 0.0131 | -0.081 ± 0.0131 | -0.065 ± 0.0132 | -0.042 ± 0.0133 | -0.085 ± 0.0137 | -0.077 ± 0.0133 | -0.020 ± 0.0133 | -0.099 ± 0.0134 | -0.092 ± 0.0132 |
The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL). Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline proinsulin/insulin ratio as continuous covariates.
| ratio | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Proinsulin/Insulin Ratio | -0.007 ± 0.0151 | -0.001 ± 0.0153 | -0.064 ± 0.0151 | -0.038 ± 0.0152 | -0.071 ± 0.0152 | -0.063 ± 0.0152 | -0.030 ± 0.0154 | -0.081 ± 0.0159 | -0.072 ± 0.0154 | -0.014 ± 0.0154 | -0.109 ± 0.0156 | -0.092 ± 0.0153 |
C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=335, 335, 336) | -0.292 ± 0.0417 | -0.255 ± 0.0417 | -0.282 ± 0.0416 |
| Week 8 (n=367, 366, 371) | -0.356 ± 0.0464 | -0.327 ± 0.0464 | -0.311 ± 0.0461 |
| Week 12 (n=367, 369, 374) | -0.268 ± 0.0781 | -0.249 ± 0.0779 | -0.334 ± 0.0774 |
| Week 16 (n=369, 374, 374) | -0.352 ± 0.0456 | -0.343 ± 0.0453 | -0.333 ± 0.0453 |
| Week 20 (n=369, 375, 375) | -0.360 ± 0.0465 | -0.350 ± 0.0461 | -0.293 ± 0.0461 |
| Week 26 (n=371, 378, 375) | -0.341 ± 0.0460 | -0.346 ± 0.0456 | -0.326 ± 0.0457 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in C-peptide Levels | 0.002 ± 0.0705 | -0.032 ± 0.0727 | 0.076 ± 0.0734 | -0.246 ± 0.0730 | -0.248 ± 0.0714 | -0.238 ± 0.0720 | -0.232 ± 0.0721 | -0.259 ± 0.0718 | -0.268 ± 0.0705 | -0.393 ± 0.0714 | -0.252 ± 0.0734 | -0.337 ± 0.0738 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in C-peptide Levels | -0.044 ± 0.0798 | 0.114 ± 0.0807 | 0.108 ± 0.0801 | -0.221 ± 0.0798 | -0.315 ± 0.0798 | -0.261 ± 0.0801 | -0.380 ± 0.0814 | -0.365 ± 0.0802 | -0.207 ± 0.0797 | -0.467 ± 0.0798 | -0.300 ± 0.0814 | -0.464 ± 0.0798 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in C-peptide Levels | -0.055 ± 0.1338 | 0.083 ± 0.1360 | 0.140 ± 0.1349 | 0.116 ± 0.1344 | -0.155 ± 0.1344 | -0.215 ± 0.1338 | -0.439 ± 0.1372 | -0.212 ± 0.1345 | -0.326 ± 0.1343 | -0.483 ± 0.1344 | -0.381 ± 0.1360 | -0.464 ± 0.1339 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in C-peptide Levels | -0.076 ± 0.0783 | 0.032 ± 0.0796 | 0.101 ± 0.0789 | -0.242 ± 0.0786 | -0.282 ± 0.0780 | -0.184 ± 0.0783 | -0.410 ± 0.0796 | -0.318 ± 0.0783 | -0.306 ± 0.0786 | -0.404 ± 0.0786 | -0.431 ± 0.0789 | -0.510 ± 0.0783 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in C-peptide Levels | -0.046 ± 0.0799 | 0.114 ± 0.0812 | 0.019 ± 0.0805 | -0.193 ± 0.0802 | -0.377 ± 0.0792 | -0.184 ± 0.0795 | -0.380 ± 0.0812 | -0.343 ± 0.0799 | -0.266 ± 0.0802 | -0.506 ± 0.0802 | -0.329 ± 0.0805 | -0.430 ± 0.0799 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline C-peptide as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in C-peptide Levels | -0.011 ± 0.0793 | 0.000 ± 0.0802 | 0.059 ± 0.0799 | -0.239 ± 0.0792 | -0.380 ± 0.0783 | -0.204 ± 0.0789 | -0.353 ± 0.0805 | -0.235 ± 0.0790 | -0.300 ± 0.0795 | -0.429 ± 0.0793 | -0.421 ± 0.0796 | -0.474 ± 0.0793 |
Change from Baseline in total cholesterol was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=345, 354, 348) | 1.6 ± 1.41 | -4.3 ± 1.39 | -6.5 ± 1.40 |
| Week 8 (n=374, 380, 376) | 4.8 ± 1.42 | -1.8 ± 1.41 | -3.3 ± 1.42 |
| Week 12 (n=374, 380, 376) | 6.6 ± 1.47 | 1.3 ± 1.46 | -1.7 ± 1.46 |
| Week 16 (n=374, 380, 376) | 6.5 ± 1.52 | 1.2 ± 1.51 | 0.1 ± 1.51 |
| Week 20 (n=374, 380, 376) | 5.9 ± 1.56 | 3.0 ± 1.55 | 1.5 ± 1.56 |
| Week 26 (n=374, 380, 376) | 8.0 ± 1.63 | 4.4 ± 1.61 | 3.9 ± 1.62 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Total Cholesterol Levels | 1.3 ± 2.40 | -3.8 ± 2.47 | -3.7 ± 2.48 | 2.1 ± 2.47 | -2.3 ± 2.42 | -10.2 ± 2.41 | 3.7 ± 2.42 | -7.2 ± 2.38 | -2.7 ± 2.41 | -1.2 ± 2.43 | -3.6 ± 2.43 | -6.7 ± 2.47 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Total Cholesterol Levels | 10.9 ± 2.46 | -1.4 ± 2.50 | -0.3 ± 2.48 | 7.3 ± 2.46 | -2.3 ± 2.43 | -4.1 ± 2.44 | 6.6 ± 2.48 | 0.1 ± 2.45 | 0.3 ± 2.47 | 0.3 ± 2.45 | -3.1 ± 2.46 | -6.2 ± 2.46 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Total Cholesterol Levels | 7.8 ± 2.54 | 0.4 ± 2.57 | 0.1 ± 2.56 | 8.7 ± 2.54 | 1.9 ± 2.51 | -0.2 ± 2.52 | 7.3 ± 2.56 | 0.3 ± 2.52 | -1.0 ± 2.55 | 3.7 ± 2.53 | 1.7 ± 2.54 | -3.9 ± 2.54 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Total Cholesterol Levels | 5.0 ± 2.62 | -0.5 ± 2.66 | -2.9 ± 2.65 | 7.2 ± 2.62 | -0.4 ± 2.59 | 3.2 ± 2.60 | 10.0 ± 2.65 | 0.9 ± 2.61 | -1.2 ± 2.63 | 2.3 ± 2.61 | 2.9 ± 2.62 | -1.8 ± 2.62 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Total Cholesterol Levels | 6.7 ± 2.70 | 1.8 ± 2.74 | -1.9 ± 2.73 | 6.3 ± 2.70 | 4.0 ± 2.67 | 1.4 ± 2.68 | 7.0 ± 2.73 | 1.1 ± 2.68 | 3.4 ± 2.71 | 4.6 ± 2.69 | 4.0 ± 2.70 | -0.3 ± 2.70 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Total Cholesterol Levels | 4.4 ± 2.82 | 2.2 ± 2.85 | 0.9 ± 2.84 | 5.8 ± 2.81 | 4.3 ± 2.78 | 3.5 ± 2.79 | 8.8 ± 2.84 | 2.8 ± 2.80 | 3.2 ± 2.83 | 9.5 ± 2.80 | 6.0 ± 2.81 | 5.1 ± 2.81 |
Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=330, 336, 338) | 3.1 ± 1.23 | -0.5 ± 1.22 | -1.9 ± 1.22 |
| Week 8 (n=365, 365, 365) | 5.9 ± 1.28 | 1.3 ± 1.28 | 0.1 ± 1.28 |
| Week 12 (n=365, 367, 366) | 6.9 ± 1.29 | 3.3 ± 1.29 | 1.5 ± 1.29 |
| Week 16 (n=365, 368, 366) | 6.1 ± 1.29 | 3.3 ± 1.29 | 2.4 ± 1.29 |
| Week 20 (n=365, 368, 366) | 6.9 ± 1.37 | 4.2 ± 1.36 | 3.0 ± 1.37 |
| Week 26 (n=365, 368, 366) | 7.4 ± 1.39 | 5.2 ± 1.39 | 5.6 ± 1.39 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Low-Density Lipoprotein Cholesterol | 2.1 ± 2.11 | -2.4 ± 2.22 | 1.4 ± 2.19 | 2.6 ± 2.16 | 1.6 ± 2.12 | -2.7 ± 2.11 | 3.2 ± 2.12 | -2.8 ± 2.09 | 0.4 ± 2.10 | 3.4 ± 2.13 | -0.3 ± 2.15 | -3.4 ± 2.13 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Low-Density Lipoprotein Cholesterol | 9.4 ± 2.24 | 2.1 ± 2.30 | 3.4 ± 2.24 | 7.3 ± 2.21 | -0.4 ± 2.21 | 1.0 ± 2.21 | 5.4 ± 2.24 | 2.4 ± 2.21 | 2.7 ± 2.24 | 4.8 ± 2.21 | 2.0 ± 2.24 | -3.2 ± 2.20 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol | 6.5 ± 2.26 | 1.9 ± 2.30 | 3.7 ± 2.26 | 8.9 ± 2.24 | 3.3 ± 2.21 | 3.8 ± 2.24 | 6.1 ± 2.26 | 1.9 ± 2.23 | 0.9 ± 2.25 | 5.7 ± 2.23 | 4.9 ± 2.26 | -0.3 ± 2.22 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Low-Density Lipoprotein Cholesterol | 4.2 ± 2.25 | 1.3 ± 2.29 | 0.9 ± 2.26 | 7.1 ± 2.23 | 2.9 ± 2.21 | 4.6 ± 2.23 | 7.1 ± 2.25 | 2.1 ± 2.23 | 0.8 ± 2.25 | 4.1 ± 2.22 | 4.9 ± 2.25 | 1.8 ± 2.21 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Low-Density Lipoprotein Cholesterol | 6.9 ± 2.39 | 2.9 ± 2.43 | 1.9 ± 2.40 | 7.7 ± 2.37 | 4.3 ± 2.34 | 3.0 ± 2.37 | 6.6 ± 2.39 | 2.3 ± 2.36 | 4.1 ± 2.39 | 6.3 ± 2.36 | 6.1 ± 2.39 | 1.9 ± 2.35 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Low-Density Lipoprotein Cholesterol | 3.6 ± 2.43 | 2.8 ± 2.47 | 3.6 ± 2.44 | 7.9 ± 2.41 | 3.7 ± 2.38 | 6.1 ± 2.41 | 6.2 ± 2.43 | 2.9 ± 2.40 | 3.0 ± 2.43 | 8.1 ± 2.40 | 9.1 ± 2.43 | 7.7 ± 2.39 |
Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=345, 353, 348) | 3.0 ± 0.33 | 2.7 ± 0.33 | 3.4 ± 0.33 |
| Week 8 (n=374, 380, 376) | 4.0 ± 0.35 | 4.1 ± 0.34 | 4.6 ± 0.35 |
| Week 12 (n=374, 380, 376) | 5.4 ± 0.37 | 5.3 ± 0.37 | 5.1 ± 0.37 |
| Week 16 (n=374, 380, 376) | 5.2 ± 0.39 | 5.2 ± 0.38 | 5.0 ± 0.38 |
| Week 20 (n=374, 380, 376) | 5.2 ± 0.40 | 5.7 ± 0.40 | 5.2 ± 0.40 |
| Week 26 (n=374, 380, 376) | 5.1 ± 0.41 | 5.5 ± 0.41 | 5.0 ± 0.41 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in High-Density Lipoprotein Cholesterol | -0.4 ± 0.57 | -0.6 ± 0.59 | -0.5 ± 0.59 | 2.5 ± 0.59 | 1.6 ± 0.58 | 1.6 ± 0.57 | 3.2 ± 0.57 | 2.3 ± 0.56 | 3.5 ± 0.57 | 3.3 ± 0.58 | 4.2 ± 0.58 | 5.1 ± 0.59 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in High-Density Lipoprotein Cholesterol | -0.5 ± 0.60 | -0.1 ± 0.61 | 0.6 ± 0.61 | 2.8 ± 0.60 | 2.3 ± 0.59 | 2.9 ± 0.60 | 4.8 ± 0.61 | 4.2 ± 0.60 | 4.6 ± 0.60 | 4.5 ± 0.60 | 5.7 ± 0.60 | 6.3 ± 0.60 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol | -0.2 ± 0.64 | 0.0 ± 0.65 | 0.3 ± 0.64 | 3.8 ± 0.64 | 3.7 ± 0.63 | 3.7 ± 0.63 | 6.3 ± 0.64 | 5.8 ± 0.63 | 5.3 ± 0.64 | 6.1 ± 0.63 | 6.3 ± 0.64 | 6.4 ± 0.64 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in High-Density Lipoprotein Cholesterol | -0.3 ± 0.67 | 0.4 ± 0.68 | 0.7 ± 0.67 | 3.9 ± 0.67 | 4.2 ± 0.66 | 4.0 ± 0.66 | 5.7 ± 0.67 | 5.5 ± 0.66 | 4.3 ± 0.67 | 5.9 ± 0.66 | 6.1 ± 0.67 | 6.7 ± 0.67 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in High-Density Lipoprotein Cholesterol | 0.6 ± 0.70 | 0.9 ± 0.71 | 0.5 ± 0.70 | 3.8 ± 0.70 | 4.3 ± 0.69 | 3.9 ± 0.69 | 5.9 ± 0.70 | 5.7 ± 0.69 | 5.3 ± 0.70 | 5.9 ± 0.70 | 7.1 ± 0.70 | 6.5 ± 0.70 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in High-Density Lipoprotein Cholesterol | 0.5 ± 0.71 | 0.6 ± 0.72 | 1.3 ± 0.71 | 3.8 ± 0.71 | 4.2 ± 0.70 | 4.1 ± 0.70 | 5.5 ± 0.71 | 6.0 ± 0.70 | 5.0 ± 0.71 | 6.1 ± 0.70 | 6.2 ± 0.71 | 6.0 ± 0.71 |
Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 4 (n=345, 354, 348) | -31.5 ± 4.07 | -38.9 ± 4.02 | -48.0 ± 4.06 |
| Week 8 (n=374, 380, 376) | -34.7 ± 4.37 | -44.4 ± 4.34 | -47.9 ± 4.36 |
| Week 12 (n=374, 380, 376) | -34.5 ± 4.25 | -47.5 ± 4.21 | -49.4 ± 4.24 |
| Week 16 (n=374, 380, 376) | -29.4 ± 4.43 | -49.3 ± 4.39 | -46.3 ± 4.42 |
| Week 20 (n=374, 380, 376) | -34.9 ± 4.30 | -43.6 ± 4.27 | -42.7 ± 4.29 |
| Week 26 (n=374, 380, 376) | -29.6 ± 4.42 | -41.4 ± 4.39 | -40.7 ± 4.41 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Triglyceride Levels | -2.4 ± 6.93 | -2.2 ± 7.15 | -25.0 ± 7.18 | -21.5 ± 7.14 | -35.8 ± 6.99 | -51.1 ± 6.96 | -26.7 ± 6.99 | -42.2 ± 6.88 | -44.4 ± 6.96 | -47.1 ± 7.02 | -39.2 ± 7.03 | -49.1 ± 7.15 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Triglyceride Levels | 26.3 ± 7.56 | -16.4 ± 7.69 | -23.0 ± 7.62 | -20.5 ± 7.56 | -30.1 ± 7.47 | -46.4 ± 7.50 | -30.3 ± 7.62 | -43.1 ± 7.51 | -44.5 ± 7.60 | -53.1 ± 7.53 | -60.1 ± 7.57 | -52.7 ± 7.56 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Triglyceride Levels | 18.9 ± 7.35 | -4.3 ± 7.44 | -18.1 ± 7.41 | -24.1 ± 7.34 | -37.4 ± 7.26 | -44.0 ± 7.29 | -37.4 ± 7.40 | -47.9 ± 7.29 | -46.8 ± 7.38 | -42.1 ± 7.31 | -57.1 ± 7.35 | -57.4 ± 7.35 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 16 in Triglyceride Levels | 10.6 ± 7.66 | -7.5 ± 7.75 | -26.8 ± 7.72 | -10.5 ± 7.66 | -53.0 ± 7.57 | -33.8 ± 7.60 | -28.2 ± 7.72 | -44.2 ± 7.60 | -45.9 ± 7.69 | -49.4 ± 7.63 | -50.7 ± 7.66 | -59.1 ± 7.66 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Triglyceride Levels | 5.7 ± 7.44 | -7.0 ± 7.53 | -23.7 ± 7.50 | -18.0 ± 7.44 | -41.2 ± 7.35 | -34.6 ± 7.38 | -37.5 ± 7.50 | -43.1 ± 7.39 | -42.4 ± 7.47 | -49.3 ± 7.41 | -46.4 ± 7.44 | -51.2 ± 7.44 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Triglyceride Levels | 3.7 ± 7.65 | -1.1 ± 7.74 | -15.2 ± 7.71 | -29.5 ± 7.65 | -37.7 ± 7.56 | -38.5 ± 7.59 | -27.0 ± 7.71 | -37.3 ± 7.59 | -33.5 ± 7.68 | -32.4 ± 7.62 | -49.3 ± 7.65 | -50.1 ± 7.65 |
Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
| mmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=339, 356, 352) | -0.0707 ± 0.01483 | -0.1306 ± 0.01447 | -0.1273 ± 0.01455 |
| Week 26 (n=353, 368, 363) | -0.0676 ± 0.01050 | -0.0945 ± 0.01029 | -0.1144 ± 0.01036 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
| mmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Free Fatty Acids | 0.0067 ± 0.02493 | -0.0149 ± 0.02535 | -0.0769 ± 0.02535 | -0.0879 ± 0.02547 | -0.1305 ± 0.02502 | -0.1291 ± 0.02512 | -0.0395 ± 0.02592 | -0.1167 ± 0.02515 | -0.1126 ± 0.02534 | -0.0848 ± 0.02567 | -0.1447 ± 0.02503 | -0.1401 ± 0.02514 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline free fatty acid as continuous covariates.
| mmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Free Fatty Acids | -0.0387 ± 0.01788 | -0.0427 ± 0.01802 | -0.0386 ± 0.01787 | -0.0561 ± 0.01825 | -0.0752 ± 0.01772 | -0.0972 ± 0.01793 | -0.0737 ± 0.01817 | -0.0956 ± 0.01788 | -0.1232 ± 0.01801 | -0.0730 ± 0.01816 | -0.1125 ± 0.01787 | -0.1228 ± 0.01787 |
Change from Baseline in plasminogen activator inhibitor-1 (PAI-1) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
| ng/mL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=311, 333, 328) | -4.14 ± 1.970 | -8.76 ± 1.900 | -8.57 ± 1.914 |
| Week 26 (n=341, 354, 348) | -4.56 ± 2.049 | -2.69 ± 2.010 | -9.25 ± 2.027 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Plasminogen Activator Inhibitor-1 | -4.55 ± 3.367 | 3.54 ± 3.350 | -1.80 ± 3.353 | -5.32 ± 3.340 | -6.28 ± 3.260 | -10.94 ± 3.320 | -8.53 ± 3.353 | -10.47 ± 3.336 | -1.71 ± 3.321 | 1.85 ± 3.539 | -9.13 ± 3.277 | -12.63 ± 3.306 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as continuous covariates.
| ng/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Plasminogen Activator Inhibitor-1 | -3.00 ± 3.526 | 0.57 ± 3.540 | -3.29 ± 3.481 | -5.43 ± 3.529 | -4.75 ± 3.465 | -9.62 ± 3.510 | -5.24 ± 3.495 | 1.89 ± 3.511 | -6.66 ± 3.525 | -3.02 ± 3.622 | -5.22 ± 3.466 | -11.48 ± 3.496 |
Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
| mg/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=346, 356, 355) | -2.0274 ± 0.32717 | -2.4653 ± 0.32225 | -1.9208 ± 0.32253 |
| Week 26 (n=359, 369, 363) | -0.8889 ± 0.46384 | -1.7716 ± 0.45715 | -0.9977 ± 0.46059 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
| mg/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in High-sensitivity C-Reactive Protein | -1.1053 ± 0.55528 | -1.0730 ± 0.56942 | 0.3516 ± 0.55954 | -0.9166 ± 0.56902 | -2.2362 ± 0.55706 | -2.4217 ± 0.55929 | -2.7023 ± 0.55971 | -2.2143 ± 0.55757 | -1.0006 ± 0.56412 | -2.4212 ± 0.57137 | -2.9032 ± 0.55979 | -2.2978 ± 0.55243 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline hsCRP as continuous covariates.
| mg/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in High-sensitivity C-Reactive Protein | -0.0550 ± 0.79868 | -0.6606 ± 0.80145 | 0.2618 ± 0.79488 | 0.2375 ± 0.80439 | -1.2490 ± 0.78817 | -0.9438 ± 0.79442 | -1.0480 ± 0.79805 | -1.1725 ± 0.79206 | 0.1697 ± 0.80434 | -1.8562 ± 0.80771 | -2.8933 ± 0.79515 | -2.2191 ± 0.79450 |
Change from Baseline in adiponectin was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
| μg/mL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=339, 357, 348) | 6.03 ± 0.353 | 6.51 ± 0.344 | 6.51 ± 0.348 |
| Week 26 (n=356, 369, 361) | 5.98 ± 0.396 | 6.43 ± 0.388 | 6.46 ± 0.393 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
| μg/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Adiponectin | 0.02 ± 0.593 | 0.44 ± 0.609 | 0.22 ± 0.606 | 3.54 ± 0.604 | 3.78 ± 0.591 | 2.91 ± 0.601 | 6.07 ± 0.617 | 6.31 ± 0.599 | 7.13 ± 0.609 | 8.47 ± 0.614 | 9.42 ± 0.598 | 9.46 ± 0.601 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline adiponectin as continuous covariates.
| μg/mL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Adiponectin | 0.43 ± 0.676 | 0.48 ± 0.681 | 0.26 ± 0.678 | 3.30 ± 0.685 | 4.80 ± 0.664 | 2.93 ± 0.678 | 5.90 ± 0.687 | 6.30 ± 0.676 | 6.87 ± 0.684 | 8.75 ± 0.684 | 8.18 ± 0.678 | 9.59 ± 0.678 |
Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
| kg | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 8 (n=361, 372, 367) | 0.45 ± 0.103 | 0.34 ± 0.101 | 0.63 ± 0.102 |
| Week 12 (n=368, 374, 373) | 0.56 ± 0.125 | 0.57 ± 0.124 | 0.82 ± 0.124 |
| Week 20 (n=368, 374, 373) | 1.21 ± 0.152 | 1.45 ± 0.151 | 1.46 ± 0.151 |
| Week 26 (n=368, 374, 373) | 1.49 ± 0.168 | 1.81 ± 0.167 | 1.87 ± 0.167 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
| kg | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 8 in Body Weight | -0.13 ± 0.176 | -0.05 ± 0.179 | -0.45 ± 0.178 | 0.32 ± 0.177 | 0.09 ± 0.174 | 0.22 ± 0.176 | 0.57 ± 0.177 | 0.49 ± 0.174 | 0.74 ± 0.177 | 0.46 ± 0.179 | 0.43 ± 0.177 | 0.93 ± 0.175 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
| kg | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Body Weight | -0.46 ± 0.216 | -0.14 ± 0.217 | -0.56 ± 0.216 | 0.39 ± 0.217 | 0.22 ± 0.213 | 0.39 ± 0.215 | 0.75 ± 0.217 | 0.60 ± 0.215 | 0.98 ± 0.216 | 0.55 ± 0.216 | 0.88 ± 0.217 | 1.08 ± 0.214 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
| kg | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 20 in Body Weight | -0.55 ± 0.263 | -0.08 ± 0.264 | -0.48 ± 0.263 | 0.76 ± 0.264 | 0.96 ± 0.259 | 0.85 ± 0.262 | 1.51 ± 0.264 | 1.45 ± 0.261 | 1.76 ± 0.263 | 1.35 ± 0.262 | 1.93 ± 0.264 | 1.76 ± 0.260 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline weight as continuous covariates.
| kg | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Body Weight | -0.66 ± 0.291 | -0.02 ± 0.292 | -0.67 ± 0.291 | 0.94 ± 0.292 | 1.25 ± 0.287 | 1.27 ± 0.290 | 1.88 ± 0.292 | 1.89 ± 0.289 | 2.10 ± 0.291 | 1.65 ± 0.290 | 2.30 ± 0.292 | 2.25 ± 0.288 |
HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
| insulin resistance | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=347, 344, 351) | -1.832 ± 0.3122 | -1.966 ± 0.3136 | -2.572 ± 0.3104 |
| Week 26 (n=348, 346, 352) | -1.571 ± 0.3501 | -2.209 ± 0.3512 | -1.711 ± 0.3481 |
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
| insulin resistance | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Calculated HOMA Insulin Resistance | 0.337 ± 0.5333 | 0.063 ± 0.5375 | 0.041 ± 0.5270 | -1.012 ± 0.5330 | -1.819 ± 0.5376 | -2.305 ± 0.5352 | -2.278 ± 0.5446 | -1.457 ± 0.5473 | -2.665 ± 0.5400 | -2.202 ± 0.5447 | -2.615 ± 0.5446 | -2.742 ± 0.5377 |
The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater degree of insulin resistance. Least Squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and HOMA-IR as continuous covariates.
| insulin resistance | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Calculated HOMA Insulin Resistance | 0.464 ± 0.5988 | 0.311 ± 0.6036 | -0.179 ± 0.5918 | -0.864 ± 0.5985 | -2.300 ± 0.5986 | -0.223 ± 0.5985 | -2.061 ± 0.6089 | -1.871 ± 0.6147 | -2.056 ± 0.6064 | -1.789 ± 0.6117 | -2.456 ± 0.6116 | -2.854 ± 0.6038 |
The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
| percentage beta cell function | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=347, 344, 350) | 2.591 ± 3.7892 | 23.799 ± 3.8017 | 19.477 ± 3.7685 |
| Week 26 (n=348, 346, 351) | 5.060 ± 3.0460 | 18.173 ± 3.0522 | 22.182 ± 3.0297 |
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
| percentage beta cell function | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Calculated HOMA Beta-cell Function | -3.027 ± 6.4915 | 16.304 ± 6.5165 | 22.996 ± 6.3854 | 2.565 ± 6.4614 | 30.346 ± 6.5157 | 19.887 ± 6.4916 | 1.118 ± 6.6030 | 21.045 ± 6.6358 | 19.935 ± 6.5444 | 4.023 ± 6.6240 | 19.938 ± 6.6025 | 18.541 ± 6.5456 |
The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population. HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as continuous covariates.
| percentage beta cell function | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Calculated HOMA Beta-cell Function | -0.924 ± 5.2260 | 11.812 ± 5.2462 | 17.814 ± 5.1407 | 2.770 ± 5.2018 | 10.977 ± 5.2010 | 19.320 ± 5.2044 | 8.983 ± 5.2921 | 22.474 ± 5.3423 | 23.475 ± 5.2687 | 3.427 ± 5.3327 | 21.068 ± 5.3154 | 23.752 ± 5.2696 |
Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=339, 354, 346) | 1.4 ± 1.00 | 0.2 ± 0.98 | 0.3 ± 0.99 |
| Week 26 (n=354, 367, 356) | -1.6 ± 1.09 | -1.5 ± 1.08 | -2.8 ± 1.09 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Apolipoprotein A1 | -1.9 ± 1.70 | -4.4 ± 1.73 | -3.0 ± 1.74 | 0.8 ± 1.73 | -1.3 ± 1.69 | 1.7 ± 1.72 | 3.5 ± 1.72 | 0.7 ± 1.69 | 0.4 ± 1.69 | -0.1 ± 1.74 | 1.1 ± 1.71 | -1.2 ± 1.72 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Apolipoprotein A1 | -4.9 ± 1.88 | -3.0 ± 1.90 | -4.2 ± 1.89 | -3.3 ± 1.90 | -3.5 ± 1.84 | -2.9 ± 1.91 | -0.2 ± 1.89 | -0.1 ± 1.86 | -3.2 ± 1.87 | -1.4 ± 1.89 | -1.0 ± 1.88 | -2.2 ± 1.89 |
Change from Baseline in Apolipoprotein A2 was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=339, 354, 345) | 3.1 ± 0.26 | 2.5 ± 0.26 | 2.3 ± 0.26 |
| Week 26 (n=354, 367, 355) | 2.4 ± 0.28 | 2.1 ± 0.27 | 1.8 ± 0.28 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Apolipoprotein A2 | 0.4 ± 0.44 | 0.1 ± 0.45 | 0.4 ± 0.45 | 2.4 ± 0.45 | 1.4 ± 0.44 | 1.9 ± 0.45 | 3.7 ± 0.45 | 2.5 ± 0.44 | 1.8 ± 0.44 | 3.0 ± 0.45 | 3.7 ± 0.45 | 3.2 ± 0.45 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Apolipoprotein A2 | 0.1 ± 0.47 | 0.2 ± 0.48 | 0.4 ± 0.48 | 1.9 ± 0.48 | 1.2 ± 0.47 | 1.0 ± 0.48 | 2.7 ± 0.48 | 2.1 ± 0.47 | 1.6 ± 0.47 | 2.8 ± 0.48 | 3.1 ± 0.47 | 2.7 ± 0.48 |
Change from Baseline in Apolipoprotein B was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=338, 354, 346) | -3.0 ± 1.09 | -7.9 ± 1.06 | -10.0 ± 1.07 |
| Week 26 (n=354, 367, 356) | -2.8 ± 1.16 | -6.4 ± 1.14 | -6.4 ± 1.15 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Apolipoprotein B | 5.0 ± 1.85 | -2.3 ± 1.87 | -3.6 ± 1.89 | -0.3 ± 1.88 | -7.2 ± 1.83 | -6.1 ± 1.87 | -2.1 ± 1.88 | -8.4 ± 1.83 | -12.2 ± 1.84 | -6.6 ± 1.90 | -8.0 ± 1.86 | -11.7 ± 1.87 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Apolipoprotein B | 0.6 ± 1.99 | -0.6 ± 2.00 | -3.7 ± 2.00 | -1.5 ± 2.01 | -6.0 ± 1.95 | -4.8 ± 2.02 | -3.2 ± 2.00 | -7.2 ± 1.97 | -8.8 ± 1.98 | -3.6 ± 2.00 | -6.1 ± 1.99 | -5.5 ± 2.00 |
Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=337, 352, 345) | -0.6 ± 0.17 | -1.2 ± 0.16 | -1.3 ± 0.17 |
| Week 26 (n=353, 366, 355) | -0.1 ± 0.19 | -0.6 ± 0.19 | -0.6 ± 0.19 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Apolipoprotein C-III | 0.7 ± 0.28 | -0.4 ± 0.29 | -0.7 ± 0.29 | -0.3 ± 0.29 | -1.0 ± 0.28 | -1.4 ± 0.29 | -0.3 ± 0.29 | -1.0 ± 0.28 | -1.3 ± 0.28 | -1.1 ± 0.29 | -1.4 ± 0.29 | -1.2 ± 0.29 |
Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Apolipoprotein C-III | 0.4 ± 0.33 | 0.5 ± 0.33 | -0.7 ± 0.33 | -0.4 ± 0.33 | -0.6 ± 0.32 | -0.7 ± 0.33 | 0.2 ± 0.33 | -0.4 ± 0.32 | -0.6 ± 0.32 | 0.0 ± 0.33 | -0.7 ± 0.33 | -0.5 ± 0.33 |
Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 345, 343) | -19.6 ± 3.92 | -28.8 ± 3.85 | -31.5 ± 3.86 |
| Week 26 (n=348, 359, 357) | -11.5 ± 4.30 | -25.4 ± 4.23 | -22.9 ± 4.24 |
NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 12. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in NMR Lipid Fractionation Total Triglycerides | 20.6 ± 6.56 | -4.9 ± 6.73 | -7.8 ± 6.70 | -12.9 ± 6.72 | -21.8 ± 6.70 | -27.2 ± 6.61 | -18.3 ± 6.82 | -29.8 ± 6.73 | -31.6 ± 6.82 | -27.9 ± 6.85 | -35.1 ± 6.59 | -36.0 ± 6.64 |
NMR lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Week 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR total triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in NMR Lipid Fractionation Total Triglycerides | 12.4 ± 7.26 | 7.3 ± 7.42 | -6.8 ± 7.32 | -18.9 ± 7.44 | -20.4 ± 7.32 | -23.1 ± 7.32 | -6.9 ± 7.44 | -23.5 ± 7.38 | -19.7 ± 7.44 | -8.6 ± 7.44 | -32.1 ± 7.29 | -25.8 ± 7.29 |
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
| nmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Total Particles - Week 12 (n=332, 345, 343) | -1.85 ± 1.803 | -6.40 ± 1.770 | -7.26 ± 1.775 |
| Total Particles - Week 26 (n=348, 359, 357) | -1.05 ± 1.999 | -1.87 ± 1.970 | -1.31 ± 1.975 |
| Large Particles - Week 12 (n=332, 345, 343) | -1.61 ± 0.289 | -2.20 ± 0.283 | -2.17 ± 0.284 |
| Large Particles - Week 26 (n=348, 359, 357) | -1.05 ± 0.342 | -2.25 ± 0.337 | -1.98 ± 0.337 |
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | 5.82 ± 3.013 | -1.59 ± 3.092 | -5.32 ± 3.077 | 2.52 ± 3.089 | -3.46 ± 3.077 | -5.57 ± 3.037 | 0.45 ± 3.135 | -7.82 ± 3.092 | -6.54 ± 3.132 | -8.58 ± 3.147 | -7.99 ± 3.027 | -9.76 ± 3.051 |
| Large Particles | 1.12 ± 0.482 | -0.42 ± 0.495 | -0.27 ± 0.493 | -1.20 ± 0.495 | -1.63 ± 0.493 | -1.81 ± 0.486 | -1.69 ± 0.502 | -2.19 ± 0.495 | -2.29 ± 0.501 | -1.97 ± 0.504 | -2.81 ± 0.484 | -2.45 ± 0.489 |
The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | 2.80 ± 3.379 | 0.59 ± 3.450 | -5.79 ± 3.405 | -2.99 ± 3.462 | -3.31 ± 3.405 | -5.15 ± 3.405 | 3.68 ± 3.464 | -0.59 ± 3.436 | -0.35 ± 3.463 | -3.83 ± 3.463 | -1.70 ± 3.394 | 1.56 ± 3.392 |
| Large Particles | 1.31 ± 0.577 | 0.94 ± 0.589 | -0.14 ± 0.582 | -1.56 ± 0.592 | -1.71 ± 0.582 | -1.80 ± 0.582 | -0.90 ± 0.592 | -2.24 ± 0.587 | -1.79 ± 0.592 | -0.67 ± 0.592 | -2.80 ± 0.580 | -2.36 ± 0.580 |
The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
| mg/dL | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 345, 343) | -20.4 ± 3.90 | -28.5 ± 3.83 | -30.3 ± 3.84 |
| Week 26 (n=348, 359, 357) | -13.0 ± 4.28 | -25.4 ± 4.22 | -23.0 ± 4.23 |
The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in VLDL / Chylomicron Triglycerides | 19.9 ± 6.51 | -3.5 ± 6.69 | -6.4 ± 6.65 | -14.2 ± 6.68 | -21.1 ± 6.65 | -26.5 ± 6.56 | -19.1 ± 6.78 | -29.5 ± 6.69 | -30.1 ± 6.77 | -28.4 ± 6.80 | -35.5 ± 6.55 | -34.8 ± 6.60 |
The change from Baseline in VLDL/chylomicron triglyceride levels was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL/chylomicron triglycerides as continuous covariates.
| mg/dL | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in VLDL / Chylomicron Triglycerides | 11.9 ± 7.23 | 8.3 ± 7.39 | -7.0 ± 7.29 | -20.4 ± 7.41 | -20.4 ± 7.29 | -23.8 ± 7.29 | -8.2 ± 7.41 | -23.5 ± 7.35 | -18.9 ± 7.41 | -10.4 ± 7.41 | -32.3 ± 7.26 | -26.2 ± 7.26 |
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.
| nmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Medium Particles - Week 12 (n=332, 345, 343) | -4.44 ± 1.174 | -5.36 ± 1.152 | -7.30 ± 1.155 |
| Medium Particles - Week 26 (n=348, 359, 357) | -2.28 ± 1.346 | -3.02 ± 1.326 | -4.88 ± 1.329 |
| Small Particles - Week 12 (n=332, 345, 343) | 4.16 ± 1.053 | 1.33 ± 1.033 | 1.91 ± 1.035 |
| Small Particles - Week 26 (n=348, 359, 357) | 2.30 ± 1.084 | 3.55 ± 1.067 | 5.22 ± 1.070 |
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medium Particles | 2.13 ± 1.962 | -1.13 ± 2.014 | -2.88 ± 2.003 | -2.25 ± 2.011 | -3.16 ± 2.004 | -6.51 ± 1.977 | -2.59 ± 2.041 | -6.70 ± 2.013 | -7.05 ± 2.039 | -8.64 ± 2.048 | -6.38 ± 1.971 | -8.50 ± 1.987 |
| Small Particles | 2.76 ± 1.758 | 0.39 ± 1.804 | -2.30 ± 1.797 | 5.99 ± 1.803 | 1.16 ± 1.796 | 2.60 ± 1.772 | 4.39 ± 1.829 | 1.15 ± 1.806 | 2.51 ± 1.828 | 2.22 ± 1.839 | 1.80 ± 1.765 | 0.73 ± 1.780 |
The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR VLDL particles as continuous covariates
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medium Particles | 1.54 ± 2.275 | 0.85 ± 2.324 | -2.94 ± 2.292 | -4.43 ± 2.331 | -1.78 ± 2.293 | -5.42 ± 2.292 | 0.28 ± 2.332 | -2.17 ± 2.313 | -4.38 ± 2.331 | -2.70 ± 2.331 | -5.09 ± 2.285 | -4.83 ± 2.284 |
| Small Particles | 0.26 ± 1.831 | -0.87 ± 1.868 | -2.91 ± 1.846 | 2.83 ± 1.876 | -0.19 ± 1.845 | 1.90 ± 1.845 | 4.16 ± 1.877 | 4.07 ± 1.863 | 5.45 ± 1.876 | -0.08 ± 1.878 | 6.77 ± 1.837 | 8.33 ± 1.837 |
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
| nm | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 344, 343) | -2.77 ± 0.398 | -2.98 ± 0.390 | -3.02 ± 0.391 |
| Week 26 (n=348, 358, 357) | -2.49 ± 0.406 | -3.67 ± 0.400 | -3.26 ± 0.400 |
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Mean VLDL Particle Size | 0.65 ± 0.664 | 0.12 ± 0.681 | -0.18 ± 0.678 | -2.81 ± 0.681 | -2.10 ± 0.681 | -2.56 ± 0.669 | -3.16 ± 0.690 | -2.88 ± 0.681 | -2.49 ± 0.690 | -2.37 ± 0.694 | -4.00 ± 0.666 | -4.03 ± 0.672 |
The change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Mean VLDL Particle Size | 0.26 ± 0.685 | 0.52 ± 0.700 | 0.35 ± 0.691 | -2.99 ± 0.703 | -2.66 ± 0.694 | -2.36 ± 0.691 | -2.88 ± 0.703 | -3.69 ± 0.697 | -3.30 ± 0.702 | -1.60 ± 0.703 | -4.65 ± 0.688 | -4.12 ± 0.688 |
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
| nmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 345, 343) | 0.4 ± 2.16 | -3.9 ± 2.12 | -5.7 ± 2.12 |
| Week 26 (n=348, 359, 357) | 2.8 ± 2.16 | -4.2 ± 2.13 | -1.5 ± 2.13 |
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in IDL Particles | 1.6 ± 3.60 | -11.1 ± 3.70 | -6.0 ± 3.68 | 5.1 ± 3.70 | -6.0 ± 3.68 | -2.3 ± 3.64 | -2.2 ± 3.75 | -6.3 ± 3.70 | -8.1 ± 3.75 | -1.5 ± 3.76 | 0.7 ± 3.62 | -6.5 ± 3.65 |
The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR IDL particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in IDL Particles | 5.1 ± 3.65 | -7.3 ± 3.73 | -3.2 ± 3.68 | 5.2 ± 3.74 | -2.4 ± 3.67 | 0.0 ± 3.68 | 3.0 ± 3.74 | -5.0 ± 3.71 | -5.5 ± 3.74 | 0.1 ± 3.74 | -5.0 ± 3.66 | 1.0 ± 3.66 |
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
| nmol/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Total Particles - Week 12 (n=332, 345, 343) | -104.1 ± 17.46 | -180.5 ± 17.13 | -236.8 ± 17.18 |
| Total Particles - Week 26 (n=348, 359, 357) | -78.2 ± 17.83 | -146.2 ± 17.55 | -182.9 ± 17.60 |
| Large Particles - Week 12 (n=332, 345, 343) | 85.5 ± 10.02 | 111.6 ± 9.83 | 102.3 ± 9.85 |
| Large Particles - Week 26 (n=348, 359, 357) | 95.8 ± 11.11 | 93.9 ± 10.93 | 106.1 ± 10.96 |
| Medium-Small Particles - Week 12 (n=332, 345, 343) | -36.6 ± 4.11 | -55.3 ± 4.03 | -60.1 ± 4.04 |
| Medium-Small Particles - Week 26 (n=348, 359, 357) | -34.3 ± 4.22 | -44.9 ± 4.16 | -49.6 ± 4.17 |
| Total Small Particles - Week 12 (n=332, 345, 343) | -191.4 ± 20.32 | -287.5 ± 19.94 | -331.4 ± 20.00 |
| Total Small Particles - Week 26 (n=348, 359, 357) | -178.1 ± 21.13 | -235.0 ± 20.81 | -285.9 ± 20.87 |
| Very Small Particles - Week 12 (n=332, 345, 343) | -154.6 ± 16.53 | -232.3 ± 16.23 | -271.3 ± 16.27 |
| Very Small Particles - Week 26 (n=348, 359, 357) | -143.6 ± 17.23 | -190.3 ± 16.97 | -236.2 ± 17.02 |
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | 52.0 ± 29.17 | -39.1 ± 29.92 | -69.9 ± 29.80 | -48.8 ± 29.91 | -143.5 ± 29.79 | -175.6 ± 29.43 | -96.2 ± 30.37 | -195.8 ± 29.93 | -248.8 ± 30.31 | -167.0 ± 30.46 | -202.2 ± 29.27 | -285.8 ± 29.52 |
| Large Particles | 4.7 ± 16.74 | 21.1 ± 17.16 | -8.0 ± 17.09 | 56.2 ± 17.15 | 73.8 ± 17.08 | 85.7 ± 16.86 | 83.9 ± 17.43 | 126.2 ± 17.18 | 105.7 ± 17.39 | 116.9 ± 17.48 | 135.2 ± 16.79 | 116.1 ± 16.95 |
| Medium-Small Particles | 9.4 ± 6.87 | -7.7 ± 7.04 | -5.1 ± 7.02 | -20.3 ± 7.04 | -41.1 ± 7.01 | -48.0 ± 6.93 | -34.4 ± 7.14 | -58.2 ± 7.05 | -64.1 ± 7.14 | -55.4 ± 7.17 | -66.8 ± 6.89 | -68.2 ± 6.96 |
| Total Small Particles | 45.1 ± 33.98 | -52.0 ± 34.83 | -56.5 ± 34.70 | -109.9 ± 34.83 | -211.0 ± 34.69 | -256.3 ± 34.26 | -184.1 ± 35.32 | -313.7 ± 34.85 | -345.4 ± 35.29 | -280.4 ± 35.46 | -337.9 ± 34.08 | -392.7 ± 34.38 |
| Very Small Particles | 36.4 ± 27.65 | -44.1 ± 28.34 | -51.9 ± 28.23 | -89.2 ± 28.33 | -170.3 ± 28.22 | -207.6 ± 27.87 | -149.8 ± 28.74 | -255.7 ± 28.36 | -281.5 ± 28.72 | -225.0 ± 28.85 | -271.0 ± 27.73 | -325.0 ± 27.97 |
The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR LDL particles as continuous covariates.
| nmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | 15.0 ± 30.11 | -14.5 ± 30.73 | -30.8 ± 30.36 | -46.3 ± 30.86 | -115.1 ± 30.35 | -119.4 ± 30.37 | -68.6 ± 30.90 | -158.9 ± 30.62 | -209.4 ± 30.85 | -119.7 ± 30.87 | -164.6 ± 30.22 | -219.9 ± 30.21 |
| Large Particles | -23.8 ± 18.77 | -12.3 ± 19.14 | 15.3 ± 18.91 | 70.5 ± 19.22 | 63.2 ± 18.90 | 93.1 ± 18.90 | 79.3 ± 19.27 | 96.6 ± 19.09 | 102.7 ± 19.22 | 137.7 ± 19.23 | 121.9 ± 18.83 | 122.7 ± 18.83 |
| Medium-Small Particles | 9.1 ± 7.14 | 0.0 ± 7.28 | -6.9 ± 7.20 | -25.8 ± 7.31 | -29.9 ± 7.19 | -36.2 ± 7.20 | -30.0 ± 7.32 | -47.4 ± 7.26 | -55.0 ± 7.31 | -47.1 ± 7.31 | -57.6 ± 7.16 | -57.8 ± 7.17 |
| Total Small Particles | 32.4 ± 35.72 | 2.2 ± 36.44 | -42.9 ± 36.00 | -122.5 ± 36.59 | -175.1 ± 35.99 | -211.5 ± 36.01 | -154.9 ± 36.60 | -248.7 ± 36.31 | -304.9 ± 36.58 | -256.9 ± 36.58 | -281.1 ± 35.82 | -341.3 ± 35.82 |
| Very Small Particles | 24.0 ± 29.13 | 2.5 ± 29.71 | -36.6 ± 29.36 | -96.3 ± 29.84 | -145.7 ± 29.35 | -174.5 ± 29.37 | -124.9 ± 29.85 | -201.6 ± 29.61 | -250.0 ± 29.83 | -209.6 ± 29.83 | -223.6 ± 29.22 | -283.9 ± 29.21 |
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
| nm | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 345, 343) | 0.43 ± 0.034 | 0.58 ± 0.034 | 0.61 ± 0.034 |
| Week 26 (n=348, 359, 357) | 0.41 ± 0.036 | 0.47 ± 0.035 | 0.54 ± 0.036 |
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Mean LDL Particle Size | -0.05 ± 0.057 | 0.13 ± 0.059 | 0.06 ± 0.059 | 0.25 ± 0.059 | 0.43 ± 0.059 | 0.49 ± 0.058 | 0.44 ± 0.060 | 0.61 ± 0.059 | 0.61 ± 0.060 | 0.58 ± 0.060 | 0.68 ± 0.058 | 0.73 ± 0.058 |
The change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Mean LDL Particle Size | -0.06 ± 0.061 | -0.01 ± 0.062 | 0.07 ± 0.061 | 0.26 ± 0.062 | 0.38 ± 0.061 | 0.41 ± 0.061 | 0.38 ± 0.062 | 0.48 ± 0.062 | 0.57 ± 0.062 | 0.59 ± 0.062 | 0.55 ± 0.061 | 0.63 ± 0.061 |
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
| μMOL/L | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Total Particles - Week 12 (n=332, 345, 343) | 0.86 ± 0.220 | 0.58 ± 0.216 | 0.43 ± 0.216 |
| Total Particles - Week 26 (n=348, 359, 357) | 0.62 ± 0.235 | 1.18 ± 0.231 | 0.78 ± 0.232 |
| Large Particles - Week 12 (n=332, 345, 343) | 0.89 ± 0.111 | 0.78 ± 0.109 | 0.89 ± 0.109 |
| Large Particles - Week 26 (n=348, 359, 357) | 0.81 ± 0.123 | 0.90 ± 0.121 | 1.01 ± 0.122 |
| Medium Particles - Week 12 (n=332, 345, 343) | 1.38 ± 0.195 | 1.16 ± 0.191 | 1.63 ± 0.191 |
| Medium Particles - Week 26 (n=348, 359, 357) | 1.34 ± 0.195 | 1.10 ± 0.192 | 1.46 ± 0.192 |
| Small Particles - Week 12 (n=332, 345, 343) | -1.35 ± 0.261 | -1.39 ± 0.256 | -2.12 ± 0.256 |
| Small Particles - Week 26 (n=348, 359, 357) | -1.45 ± 0.261 | -0.85 ± 0.257 | -1.73 ± 0.258 |
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
| μmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | -0.08 ± 0.368 | -0.06 ± 0.377 | 0.16 ± 0.375 | 0.90 ± 0.377 | 0.37 ± 0.375 | 0.55 ± 0.370 | 1.29 ± 0.382 | 0.75 ± 0.377 | 0.15 ± 0.382 | 0.40 ± 0.384 | 0.63 ± 0.369 | 0.60 ± 0.372 |
| Large Particles | -0.21 ± 0.185 | -0.29 ± 0.190 | -0.10 ± 0.189 | 0.53 ± 0.190 | 0.24 ± 0.189 | 0.50 ± 0.186 | 1.09 ± 0.192 | 0.95 ± 0.190 | 1.12 ± 0.192 | 1.06 ± 0.193 | 1.17 ± 0.186 | 1.06 ± 0.187 |
| Medium Particles | 0.17 ± 0.325 | -0.24 ± 0.333 | -0.01 ± 0.332 | 0.81 ± 0.334 | 1.15 ± 0.332 | 0.65 ± 0.328 | 1.21 ± 0.338 | 0.97 ± 0.334 | 1.89 ± 0.338 | 2.06 ± 0.339 | 1.30 ± 0.326 | 2.31 ± 0.329 |
| Small Particles | -0.07 ± 0.435 | 0.43 ± 0.447 | 0.27 ± 0.445 | -0.25 ± 0.446 | -1.09 ± 0.445 | -0.63 ± 0.439 | -0.92 ± 0.453 | -1.18 ± 0.447 | -2.82 ± 0.452 | -2.82 ± 0.455 | -1.84 ± 0.437 | -2.84 ± 0.441 |
The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR lipid fractionation. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline NMR HDL particles as continuous covariates.
| μmol/L | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Particles | 0.18 ± 0.397 | 0.43 ± 0.405 | 1.03 ± 0.400 | 0.37 ± 0.407 | 0.77 ± 0.400 | 1.31 ± 0.400 | 0.67 ± 0.407 | 1.15 ± 0.403 | 0.26 ± 0.406 | 0.83 ± 0.407 | 1.61 ± 0.398 | 0.77 ± 0.398 |
| Large Particles | 0.02 ± 0.208 | -0.16 ± 0.212 | 0.39 ± 0.210 | 0.53 ± 0.213 | 0.55 ± 0.210 | 0.75 ± 0.210 | 0.64 ± 0.213 | 1.13 ± 0.212 | 1.34 ± 0.213 | 1.26 ± 0.213 | 1.02 ± 0.209 | 0.95 ± 0.209 |
| Medium Particles | 0.13 ± 0.330 | 0.16 ± 0.336 | 0.54 ± 0.332 | 0.81 ± 0.338 | 0.86 ± 0.332 | 0.67 ± 0.332 | 1.48 ± 0.338 | 1.47 ± 0.335 | 1.69 ± 0.337 | 1.71 ± 0.337 | 0.96 ± 0.331 | 2.01 ± 0.330 |
| Small Particles | 0.00 ± 0.441 | 0.41 ± 0.450 | 0.10 ± 0.444 | -0.78 ± 0.452 | -0.68 ± 0.444 | -0.17 ± 0.444 | -1.35 ± 0.452 | -1.47 ± 0.448 | -2.77 ± 0.452 | -2.21 ± 0.452 | -0.40 ± 0.443 | -2.24 ± 0.442 |
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. This analysis compared the groupings of participants who received the combination of pioglitazone with each dose of alogliptin with the grouping of participants who received pioglitazone alone. Least squares means are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
| nm | Pioglitazone Alone | Alogliptin 12.5 + Pioglitazone | Alogliptin 25 + Pioglitazone |
|---|---|---|---|
| Week 12 (n=332, 345, 343) | 0.11 ± 0.013 | 0.13 ± 0.013 | 0.16 ± 0.013 |
| Week 26 (n=348, 359, 357) | 0.11 ± 0.015 | 0.12 ± 0.014 | 0.17 ± 0.014 |
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 12 in Mean HDL Particle Size | 0.00 ± 0.023 | 0.00 ± 0.023 | 0.00 ± 0.023 | 0.06 ± 0.023 | 0.07 ± 0.023 | 0.09 ± 0.023 | 0.10 ± 0.023 | 0.15 ± 0.023 | 0.17 ± 0.023 | 0.18 ± 0.024 | 0.17 ± 0.023 | 0.21 ± 0.023 |
The change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation. Least squares means are from are from an ANCOVA model with treatment and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as continuous covariates.
| nm | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline to Week 26 in Mean HDL Particle Size | 0.03 ± 0.025 | 0.00 ± 0.025 | 0.07 ± 0.025 | 0.06 ± 0.025 | 0.06 ± 0.025 | 0.11 ± 0.025 | 0.10 ± 0.025 | 0.15 ± 0.025 | 0.20 ± 0.025 | 0.19 ± 0.025 | 0.16 ± 0.025 | 0.19 ± 0.025 |
Collected over Adverse events were collected from the time of informed consent until the end of the study, and from spontaneous reporting for 30 days after the end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/129 (1.6%) | 41/129 (31.8%) |
| Alogliptin 12.5 + Placebo | — | 5/128 (3.9%) | 40/128 (31.3%) |
| Alogliptin 25 + Placebo | — | 6/129 (4.7%) | 46/129 (35.7%) |
| Placebo + Pioglitazone 15 | — | 1/129 (0.8%) | 51/129 (39.5%) |
| Alogliptin 12.5 + Pioglitazone 15 | — | 2/130 (1.5%) | 45/130 (34.6%) |
| Alogliptin 25 + Pioglitazone 15 | — | 1/130 (0.8%) | 44/130 (33.8%) |
| Placebo + Pioglitazone 30 | — | 2/129 (1.6%) | 40/129 (31%) |
| Alogliptin 12.5 + Pioglitazone 30 | — | 3/130 (2.3%) | 35/130 (26.9%) |
| Alogliptin 25 + Pioglitazone 30 | — | 6/130 (4.6%) | 51/130 (39.2%) |
| Placebo + Pioglitazone 45 | — | 10/129 (7.8%) | 40/129 (31%) |
| Alogliptin 12.5 + Pioglitazone 45 | — | 2/130 (1.5%) | 47/130 (36.2%) |
| Alogliptin 25 + Pioglitazone 45 | — | 5/130 (3.8%) | 41/130 (31.5%) |
| Event | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PancreatitisGastrointestinal disorders | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| PeriodontitisGastrointestinal disorders | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| CholelithiasisHepatobiliary disorders | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| Urinary tract infectionInfections and infestations | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| Nerve compressionNervous system disorders | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/129 | 1/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| Coronary artery diseaseCardiac disorders | 0/129 | 0/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 1/129 | 0/130 | 0/130 |
| Myocardial infarctionCardiac disorders | 0/129 | 0/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 1/129 | 0/130 | 0/130 |
| Umbilical herniaGastrointestinal disorders | 0/129 | 0/128 | 0/129 | 0/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 | 1/129 | 0/130 | 0/130 |
| Non-cardiac chest painGeneral disorders | 0/129 | 0/128 | 1/129 | 0/129 | 0/130 | 0/130 | 1/129 | 0/130 | 0/130 | 0/129 | 0/130 | 0/130 |
| Event | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/129 | 5/128 | 9/129 | 16/129 | 5/130 | 3/130 | 2/129 | 2/130 | 5/130 | 5/129 | 6/130 | 6/130 |
| Back painMusculoskeletal and connective tissue disorders | 5/129 | 1/128 | 7/129 | 5/129 | 6/130 | 5/130 | 3/129 | 2/130 | 8/130 | 4/129 | 12/130 | 3/130 |
| DiarrhoeaGastrointestinal disorders | 11/129 | 2/128 | 4/129 | 5/129 | 3/130 | 6/130 | 4/129 | 2/130 | 7/130 | 5/129 | 4/130 | 7/130 |
| InfluenzaInfections and infestations | 3/129 | 4/128 | 4/129 | 9/129 | 4/130 | 8/130 | 7/129 | 2/130 | 8/130 | 5/129 | 3/130 | 2/130 |
| NasopharyngitisInfections and infestations | 5/129 | 5/128 | 4/129 | 3/129 | 8/130 | 8/130 | 4/129 | 5/130 | 9/130 | 4/129 | 6/130 | 4/130 |
| HypertensionVascular disorders | 4/129 | 6/128 | 4/129 | 6/129 | 9/130 | 3/130 | 2/129 | 3/130 | 3/130 | 2/129 | 5/130 | 1/130 |
| Urinary tract infectionInfections and infestations | 6/129 | 6/128 | 5/129 | 7/129 | 5/130 | 6/130 | 8/129 | 4/130 | 4/130 | 8/129 | 5/130 | 5/130 |
| Upper respiratory tract infectionInfections and infestations | 5/129 | 3/128 | 8/129 | 3/129 | 2/130 | 4/130 | 1/129 | 5/130 | 4/130 | 2/129 | 4/130 | 4/130 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 3/129 | 7/128 | 6/129 | 5/129 | 2/130 | 3/130 | 5/129 | 2/130 | 4/130 | 3/129 | 3/130 | 1/130 |
| DyslipidaemiaMetabolism and nutrition disorders | 0/129 | 1/128 | 1/129 | 3/129 | 3/130 | 1/130 | 2/129 | 1/130 | 4/130 | 7/129 | 1/130 | 2/130 |
| Age Continuous(years) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55.2 ± 9.89 | 53.1 ± 9.59 | 53.7 ± 9.31 | 54.1 ± 9.54 | 53.6 ± 9.91 | 54.9 ± 9.18 | 56.1 ± 9.43 | 55.0 ± 9.07 | 54.4 ± 9.69 | 54.5 ± 9.70 | 54.0 ± 9.82 | 54.2 ± 8.86 | 54.4 ± 9.50 |
| Age, Customized(participants) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 106 | 116 | 112 | 113 | 109 | 112 | 101 | 111 | 107 | 112 | 111 | 112 | 1322 |
| ≥65 years | 23 | 12 | 17 | 17 | 21 | 18 | 28 | 19 | 23 | 17 | 19 | 18 | 232 |
| Sex: Female, Male(Participants) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 68 | 61 | 79 | 69 | 70 | 69 | 66 | 76 | 75 | 76 | 70 | 78 | 857 |
| Male | 61 | 67 | 50 | 61 | 60 | 61 | 63 | 54 | 55 | 53 | 60 | 52 | 697 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 63 | 60 | 63 | 63 | 55 | 57 | 67 | 66 | 62 | 61 | 63 | 65 | 745 |
| Not Hispanic or Latino | 66 | 68 | 66 | 67 | 75 | 73 | 62 | 64 | 68 | 68 | 67 | 65 | 809 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
| Asian | 5 | 14 | 15 | 11 | 9 | 7 | 10 | 5 | 12 | 12 | 8 | 12 | 120 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 6 | 5 | 8 | 4 | 3 | 6 | 2 | 5 | 9 | 9 | 3 | 68 |
| White | 93 | 89 | 80 | 85 | 95 | 96 | 96 | 107 | 85 | 85 | 92 | 93 | 1096 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 23 | 19 | 29 | 26 | 20 | 22 | 17 | 15 | 28 | 23 | 21 | 22 | 265 |
| Weight(kg) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 83.38 ± 18.378 | 84.63 ± 19.378 | 83.25 ± 18.326 | 84.68 ± 18.634 | 85.95 ± 18.498 | 82.90 ± 16.570 | 85.86 ± 20.347 | 83.68 ± 18.340 | 85.77 ± 18.844 | 82.10 ± 17.019 | 85.01 ± 18.536 | 82.79 ± 18.768 | 84.17 ± 18.470 |
| Height(cm) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 164.48 ± 10.157 | 164.61 ± 10.614 | 162.38 ± 9.790 | 164.25 ± 11.007 | 164.59 ± 10.841 | 163.74 ± 10.456 | 164.59 ± 9.724 | 163.63 ± 11.036 | 163.64 ± 9.548 | 163.14 ± 10.961 | 163.82 ± 10.708 | 163.73 ± 11.432 | 163.88 ± 10.522 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Alogliptin 12.5 + Placebo | Alogliptin 25 + Placebo | Placebo + Pioglitazone 15 | Alogliptin 12.5 + Pioglitazone 15 | Alogliptin 25 + Pioglitazone 15 | Placebo + Pioglitazone 30 | Alogliptin 12.5 + Pioglitazone 30 | Alogliptin 25 + Pioglitazone 30 | Placebo + Pioglitazone 45 | Alogliptin 12.5 + Pioglitazone 45 | Alogliptin 25 + Pioglitazone 45 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 30.59 ± 4.808 | 30.96 ± 5.133 | 31.48 ± 5.733 | 31.25 ± 5.280 | 31.53 ± 4.979 | 30.78 ± 4.723 | 31.41 ± 5.391 | 31.09 ± 5.054 | 31.86 ± 5.585 | 30.69 ± 4.721 | 31.51 ± 5.206 | 30.62 ± 4.751 | 31.15 ± 5.122 |
2 further baseline measures are reported on the registry.
The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 5 years 1 month after primary completion. A results delay was requested in Jul 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Pioglitazone